Our CMC Consultants
At Drug Discovery Alliances, we partner with a highly vetted network of experienced CMC consultants, offering deep expertise across biologics, small molecules, and complex development programs. Our consultant profiles are now available to provide greater transparency into the qualifications and capabilities behind each engagement. If there's a specific consultant you’d like to work with, please indicate that preference on the intake form—otherwise, our team will thoughtfully match you with the expert best suited to your project needs.
Andrew Patron
Andrew is a seasoned chemistry and innovation leader with over 20 years of experience spanning synthetic chemistry, drug discovery, and sensory science. Most recently, he served as Senior Vice President of Small Molecule Discovery at Osmo, where he led efforts combining AI and chemistry to develop novel fragrance ingredients for health and wellness applications.
Previously, he held leadership roles at Firmenich (formerly Senomyx), contributing to the discovery of natural sweeteners, enhancers, and cooling agents now used in food, beverage, and pharmaceutical products. He also supported strategic partnerships, including a long-term collaboration with PepsiCo.
Andrew’s earlier career includes roles at TransTech Pharma, Biocept, and Ontogen, advancing drug discovery platforms and novel APIs. He holds a Ph.D. in Chemistry from the University of California, San Diego, and is an inventor on numerous patents across synthetic chemistry and sensory modulation.
Andy Thompson
Andy is a highly experienced organic chemist with over 40 years in the field. After earning a BS in Chemistry from the State University of New York at Buffalo, he completed a PhD in Organic Synthesis at the University of Pennsylvania, followed by an NIH Postdoctoral Fellowship at the University of California, Irvine.
He began his career as a Process Chemist at Merck, where he worked in Process Research for nearly a decade. In 1996, he founded a world-leading process research company, serving as President and CEO until 2023. Now working as an independent consultant, he specializes in solving complex organic chemistry challenges and providing strategic guidance for IND-enabling work, helping advance development candidates from discovery to Phase I clinical trials.
Bette Monnot-Chase
Bette is a pharmaceutical development expert with over 25 years of experience in analytical development, formulation, and quality systems. She has played a key role in supporting the development of novel therapeutics, contributing to multiple approved NDAs and MAAs. Her expertise spans method development, validation, stability programs, and reference standard management across various dosage forms, including parenteral, inhalable, and oral solid and liquid products.
Having worked with companies such as Marinus Pharmaceuticals, Asklepion Pharmaceuticals, ViroPharma (now Takeda), Cephalon (now Teva), and Magellan Laboratories (now Catalent), she has extensive experience in small-molecule drug development. She is a strong advocate for the principles of ICH Q14, ensuring analytical methods are designed for selectivity, stability, and regulatory compliance. A frequent speaker at industry conferences, she brings deep knowledge in stability programs, reference standards, and analytical method development to support global clinical and commercial drug programs.
Brian Marron
Brian is the Founder and President of his own Consulting LLC, specializing in advancing drug discovery projects through strategic consulting. With over 30 years of experience in medicinal chemistry and pharmaceutical R&D, he has held leadership roles at Tetra Therapeutics, Pfizer, Icagen, and GSK. His expertise spans drug discovery strategy, lead optimization, formulation development, CRO management, and intellectual property evaluation. He has contributed to the development of key therapeutics, including relutrigine (PRAX-562) and Prax-20. His extensive industry experience enables him to guide clients in optimizing their R&D efforts from discovery to commercialization.
Gary Dull
Gary brings over 27 years of experience in drug discovery and pharmaceutical development, with a background in Organic and Medicinal Chemistry and a minor in Food Science. He holds 74 U.S. patents and specializes in API scale-up, process development, GMP manufacturing, regulatory submissions (INDs, NDAs), and contract outsourcing.
He has led and mentored teams in medicinal, analytical, and process chemistry for over 16 years and has served on the IRB at Atrium Health Wake Forest Baptist for more than 19 years.
As a consultant, he provides strategic guidance on CMC development and regulatory filings. With over 13 years in the tobacco industry, he has contributed to PMTA submissions, synthetic nicotine, and ENDS technologies—earning 10 related patents. His expertise is supported by multiple publications and conference presentations.
Rowena Choudrie
Rowena is a seasoned pharmaceutical development leader with over 30 years of experience in CMC (Chemistry, Manufacturing, and Controls), product and process development, and clinical manufacturing. She has led CMC teams at Bristol Myers Squibb, and Celgene and she has held senior leadership roles at Actinium Pharmaceuticals, NPS Pharmaceuticals, and Schering-Plough. With expertise spanning drug product development, process optimization, technology transfers, and regulatory strategy, she has been instrumental in bringing innovative therapies to market. Additionally, as a former adjunct professor at Stevens Institute of Technology, she has contributed to the advancement of pharmaceutical manufacturing education.
